



Customer No. 36441 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/854,883
Applicant : Cowsert, et al.
Filed : May 14, 2001
TC/A.U. : 1635
Customer No. : 36441
Title : ANTISENSE MODULATION OF PTP1B
EXPRSSION

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FOURTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith.

Pursuant to 37 CFR § 1.97 (e) (1), each item of information contained in this Information Disclosure Statement (IDS) was first cited in a communication from a foreign patent office in a related European application not more than three months prior to the filing of this IDS. Therefore, no fees are believed due.

CERTIFICATE UNDER 37 CFR 1.8
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 17, 2004.

Signature Kelly A. Karstadt
Typed or Printed Kelly A. Karstadt

REMARKS

Listed below are documents cited in the Supplementary European Search Report dated April 6, 2004 in the related European Application Number 01 90 0829. A copy of the Report is enclosed, together with copies of the documents.

- (1) **HENRY, S.P, et al.** "Toxicology and Pharmacokinetic Properties of Chemically Modified Antisense Oligonucleotide Inhibitors of PKC-Alpha and C-Raf Kinase", Anti-Cancer Drug Design, Basingstoke, GB, Vol. 12 No. 5, Pages 409-420 (July 1997)
- (2) **HO, SIEW PENG, et al.** "Mapping Of RNA Accessible Sites For Antisense Experiments With Oligonucleotide Libraries", Nature Biotechnology, Nature Publishing Vol. 16 No. 1 pages 59-63 (January 1998)

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,
HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
(215) 540-9200

Customer No. 36441 PATENT



PTO/SB/08b (08-03)
 Approved for use through 7/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/854,883
				Filing Date	May 14, 2001
				First Named Inventor	Cowsert, et al.
				Group Art Unit	1635
				Examiner Name	J. Zara
Sheet	1	of	1	Attorney Docket Number	ISPH-0576

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AA	HENRY, S.P, et al. "Toxicology and Pharmacokinetic Properties of Chemically Modified Antisense Oligonucleotide Inhibitors of PKC-Alpha and C-Raf Kinase", Anti-Cancer Drug Design, Basingstoke, GB, Vol. 12 No. 5, Pages 409-420 (July 1997)	
	AB	HO, SIEW PENG, et al. "Mapping Of RNA Accessible Sites For Antisense Experiments With Oligonucleotide Libraries", Nature Biotechnology, Nature Publishing Vol. 16 No. 1 pages 59-63 (January 1998)	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.